Lucid Diagnostics Inc.
LUCD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4 | $2 | $0 | $1 |
| % Growth | 79% | 544% | -24.6% | – |
| Cost of Goods Sold | $8 | $8 | $4 | $1 |
| Gross Profit | -$4 | -$6 | -$3 | -$0 |
| % Margin | -90.2% | -249.2% | -858.6% | -17% |
| R&D Expenses | $6 | $7 | $11 | $9 |
| G&A Expenses | $20,156 | $19 | $24 | $13 |
| SG&A Expenses | $36,619 | $36 | $40 | $18 |
| Sales & Mktg Exp. | $16,463 | $16 | $16 | $5 |
| Other Operating Expenses | -$36,583 | -$0 | $2 | $0 |
| Operating Expenses | $42 | $42 | $53 | $27 |
| Operating Income | -$46 | -$48 | -$56 | -$27 |
| % Margin | -1,059.6% | -1,996.8% | -14,899.5% | -5,483.8% |
| Other Income/Exp. Net | $1 | -$4 | $0 | -$1 |
| Pre-Tax Income | -$46 | -$53 | -$56 | -$28 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$46 | -$53 | -$56 | -$28 |
| % Margin | -1,047.6% | -2,169.1% | -14,899.5% | -5,615.6% |
| EPS | -1.05 | -1.26 | -1.55 | -0.78 |
| % Growth | 16.7% | 18.7% | -98.7% | – |
| EPS Diluted | -1.05 | -1.26 | -1.55 | -0.78 |
| Weighted Avg Shares Out | 51 | 42 | 36 | 36 |
| Weighted Avg Shares Out Dil | 51 | 42 | 36 | 36 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $1 | $2 | $2 | $0 |
| EBITDA | -$44 | -$50 | -$54 | -$27 |
| % Margin | -1,020.2% | -2,049.1% | -14,385.9% | -5,483% |